Clinical Trial Update: Olaparib + Sapacitabine in BRCA Mutant Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial updating the combination of olaparib with sapacitabine in BRCA-mutant breast cancer. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lynparza (olaparib)
• Sapacitabine (sapacitabine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING